尽管每个季度都会亏损,但经打压收入估计数后,Ventyx生物科学公司的股份上升了13.5%。 Ventyx Biosciences shares rose 13.5% after beating earnings estimates, despite a quarterly loss.

在报告第四季度每股亏损0.32美元(每股亏损0.13美元)之后,VTYX(VTYX)股票在星期五猛涨13.5%至8.7850美元,达到8.80美元的最高水平。 Ventyx Biosciences (VTYX) shares surged 13.5% to $8.7850 on Friday, reaching a session high of $8.80, after reporting a fourth-quarter loss of $0.32 per share—beating estimates by $0.13. 股票上涨是在分析师升级之后进行的,其中包括Canacord Genuity公司16.00美元的目标,Wells Fargo公司14.00美元的目标,这有助于达成共识的“机动购买”评级和15.50美元平均价格目标。 The stock rise followed analyst upgrades, including a $16.00 target from Canaccord Genuity and a $14.00 target from Wells Fargo, contributing to a consensus "Moderate Buy" rating and a $15.50 average price target. 该公司正在开发针对炎症性疾病的小分子疗法，并在银屑病、溃疡性结肠炎及低效磷相关周期性综合征的临床试验中领先。 The company, developing small molecule therapies for inflammatory diseases, has lead candidates in clinical trials for psoriasis, ulcerative colitis, and cryopyrin-associated periodic syndrome. 内幕John Nuss以7.72美元出售12 675股股票,将股份减少2.52%。 Insider John Nuss sold 12,675 shares at $7.72, reducing his stake by 2.52%. 股票关闭时超过50天移动平均数7.79美元,市场上限为6.2476亿美元,P/E比率为负-5.84。 The stock closed above its 50-day moving average at $7.79, with a market cap of $624.76 million and a negative P/E ratio of -5.84.